{"id":1949,"date":"2016-10-18T12:40:15","date_gmt":"2016-10-18T12:40:15","guid":{"rendered":"http:\/\/www.caltagmedsystems.co.uk\/information\/?p=1949"},"modified":"2022-06-21T15:22:02","modified_gmt":"2022-06-21T15:22:02","slug":"september-2016-the-antibody-update","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/september-2016-the-antibody-update\/","title":{"rendered":"September 2016: The Antibody Update From ProSci"},"content":{"rendered":"

ProSci’s<\/a> top news picks for September 2016 include a paper on a novel monoclonal antibody against parenchymal amyloid-beta for the treatment of Alzheimer’s Dementia, a scientist using CRISPR for gene editing of embryos, and an update on the discussion of antibody validation.<\/p>\n

 A Monoclonal Antibody Against Amyloid-Beta Plaques Strengthens the Amyloid Hypothesis<\/h4>\n

Aducanumab<\/a> is a novel monoclonal antibody that has been designed to target the amyloid-beta plaques closely associated with Alzheimer\u2019s disease. Specifically, Aducanumab is a murine IgG2a\/\u03ba chimeric analogue capable of binding parenchymal amyloid-beta plaques built up in brain tissue, and was shown to remove upwards of 50% of plaques. Treatment of patients with mild cases of Alzheimer\u2019s dementia with monthly intravenous infusions of Aducanumab showed a slowing of clinical decline on several scales measuring dementia\u2019s severity, lending support to the amyloid hypothesis.<\/p>\n

 <\/p>\n

Embryonic Research Using CRISPR is Taking Place in Sweden<\/h4>\n

For the last several years, human embryonic research in vitro has been limited due to ethical concerns, but Swedish scientist Fredrik Lanner has been using CRISPR\/Cas9 to begin studying the earliest stages of human development. The full story<\/a> published by NPR discusses how Lanner\u2019s work using CRISPR walks along the fine line between the ethics of studying the human embryo and the scientific curiosity. Lanner\u2019s latest paper on X-chromosome inactivation using this system was published in early August, and can be seen here.<\/a><\/p>\n

 <\/p>\n

 <\/p>\n

Antibody Validation May Be Taking a Step Toward Product Ranking<\/h4>\n

Antibody development companies have been working to establish a standard of validation to potentially resolve some issues with reproducibility. This article t<\/a>akes a look at a meeting that was held amongst antibody developers, where potential resolutions were discussed. One idea is to rank antibodies according to their performance in specific applications, which is paramount to the experiment\u2019s success. This would be an extremely work intensive process to perform for many companies, but it could provide a great benefit to researchers, prevent poor data from impacting the results and reproducibility of their work.<\/p>\n

Find out how ProSci can help your Antibody needs today!<\/a><\/p>\n

Originally posted by ProSci<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

ProSci’s top news picks for September 2016 include a paper on a novel monoclonal antibody against parenchymal amyloid-beta for the treatment of Alzheimer’s Dementia, a scientist using CRISPR for gene editing of embryos, and an update on the discussion of<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[198,197,165,199,146,186,77,190,139,155],"class_list":["post-1949","post","type-post","status-publish","format-standard","hentry","category-antibodies","tag-alzheimers","tag-antibodu-update","tag-cell-biology","tag-crispr","tag-monoclonal-antibodies","tag-neuroscience","tag-prosci","tag-sfn","tag-therapeutics","tag-validation"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=1949"}],"version-history":[{"count":17,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1949\/revisions"}],"predecessor-version":[{"id":6725,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/1949\/revisions\/6725"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=1949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=1949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=1949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}